BlossomHill Therapeutics Secures $84 Million to Advance First-in-Class EGFR Inhibitor for Lung Cancer
Key Insights
BlossomHill Therapeutics (search) closed an $84 million Series B extension, bringing total capital raised to $257 million to accelerate development of two lead cancer programs.
The company's BH-30643 is a first-in-class macrocyclic OMNI-EGFR (search) inhibitor showing systemic and CNS anti-tumor activity in EGFR-mutant NSCLC patients with complex resistance mutations.
BH-30236, a novel CLK (search) inhibitor targeting aberrant RNA splicing, has commenced combination studies with venetoclax in relapsed/refractory AML and high-risk MDS patients.
BlossomHill Therapeutics (search) announced the closing of an $84 million Series B extension financing on December 10, 2025, bringing the clinical-stage biopharmaceutical company's total capital raised to $257 million. The proceeds will accelerate development of the company's two lead clinical programs targeting difficult-to-treat cancers, including a first-in-class EGFR (search) inhibitor for non-small cell lung cancer.
The financing was led by new investors Janus Henderson Investors (search), Brahma Capital (search), and BioTrack Capital (search), with participation from existing investors including Cormorant Asset Management (search), OrbiMed (search), Plaisance Capital Management LLC, and Vivo Capital.
Novel EGFR Inhibitor Shows Promise in Resistant Lung Cancer
BlossomHill's lead program, BH-30643, represents a first-in-class, orally available, macrocyclic, CNS-active, mutant-selective OMNI-EGFR (search) inhibitor designed for super-potency against a broad spectrum of EGFR kinase domain mutations. The drug targets EGFR classical mutations, atypical mutations such as PACC mutations, and diverse resistant mutations including C797S +/- T790M.
The company has commenced enrollment in expansion cohorts of the Phase 1/2 SOLARA trial, evaluating BH-30643 in both targeted therapy-naive and pretreated patients with locally advanced or metastatic EGFR (search)-mutant NSCLC. Preliminary data from the dose escalation portion, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, demonstrated systemic and CNS anti-tumor activity across various advanced EGFR-mutant NSCLCs with complex and difficult-to-treat resistance mutations.
BH-30643 is designed to spare wild-type EGFR (search) and HER2 (search) inhibition through selective targeting of the active conformation of kinases, potentially reducing associated toxicity. The drug is currently being evaluated in patients with locally advanced or metastatic NSCLC bearing EGFR and/or HER2 mutations.
CLK Inhibitor Targets RNA Splicing in Blood Cancers
The company's second lead program, BH-30236, is a novel, orally available, macrocyclic inhibitor of CDC-like kinase (CLK (search)). By modulating RNA splicing through CLK enzyme inhibition, BH-30236 aims to address aberrant splicing events that drive tumor growth and disease progression in hematological malignancies and solid tumors.
BlossomHill has commenced combination enrollment with venetoclax in the first-in-human, Phase 1/1b dose escalation study of BH-30236 in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). A trial-in-progress poster was recently presented at the 67th American Society of Hematology Annual Meeting and Exposition.
Leadership and Clinical Timeline
"With clinical data beginning to come into focus across both of our lead programs, momentum is building at BlossomHill Therapeutics (search)," said J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill. "We are delighted by the strong vote of confidence from new and existing investors in this financing, which arrives at a critical juncture as we drive our clinical programs forward and leverage our established track record in oncology drug design to address the challenges of cancer treatment resistance and deliver meaningful benefit for cancer patients."
Vish Sridharan, M.D., of Janus Henderson Investors (search), commented: "BlossomHill has pioneered novel macrocyclic molecules that could potentially make a profound impact in the treatment of EGFR (search) mutant lung cancer, and could potentially use the same platform towards elevating the standard of care for patients across other high-unmet need malignancies."
Updates from both the Phase 1/2 SOLARA trial of BH-30643 and the first-in-human Phase 1/1b dose escalation study of BH-30236 are expected in 2026.
Company Background
BlossomHill Therapeutics (search) is a privately held, clinical-stage biopharmaceutical company founded and led by industry veteran J. Jean Cui, Ph.D., who has a proven track record in oncology drug design and development, including three FDA-approved drugs. The San Diego-based company focuses on designing and developing next-generation targeted therapies for cancer, applying cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers.